JP2002525086A - 血小板由来増殖因子ｃ、それをコードするｄｎａ、及びその利用法 - Google Patents

血小板由来増殖因子ｃ、それをコードするｄｎａ、及びその利用法

Info

Publication number
JP2002525086A
JP2002525086A JP2000571742A JP2000571742A JP2002525086A JP 2002525086 A JP2002525086 A JP 2002525086A JP 2000571742 A JP2000571742 A JP 2000571742A JP 2000571742 A JP2000571742 A JP 2000571742A JP 2002525086 A JP2002525086 A JP 2002525086A
Authority
JP
Japan
Prior art keywords
pdgf
polypeptide
vegf
nucleic acid
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000571742A
Other languages
English (en)
Japanese (ja)
Inventor
エリクソン，ウルフ
アーセ，カリン
リ，シュリ
ポンテン，アンニカ
ウーテラ，マルコ
アリタロ，カリ
エストマン，アルネ
ヘルディン，カール‐ヘンリック
ベトショルツ，クリスター
Original Assignee
ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ
ライセンティア・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ, ライセンティア・リミテッド filed Critical ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ
Publication of JP2002525086A publication Critical patent/JP2002525086A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2000571742A 1998-09-30 1999-09-30 血小板由来増殖因子ｃ、それをコードするｄｎａ、及びその利用法 Pending JP2002525086A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US10246198P 1998-09-30 1998-09-30
US60/102,461 1998-09-30
US10810998P 1998-11-12 1998-11-12
US60/108,109 1998-11-12
US11074998P 1998-12-03 1998-12-03
US60/110,749 1998-12-03
US11300298P 1998-12-18 1998-12-18
US60/113,002 1998-12-18
US13542699P 1999-05-21 1999-05-21
US60/135,426 1999-05-21
US14402299P 1999-07-15 1999-07-15
US60/144,022 1999-07-15
PCT/US1999/022668 WO2000018212A2 (fr) 1998-09-30 1999-09-30 Facteur de croissance c derive des plaquettes, adn le codant et ses utilisations

Publications (1)

Publication Number Publication Date
JP2002525086A true JP2002525086A (ja) 2002-08-13

Family

ID=27557649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000571742A Pending JP2002525086A (ja) 1998-09-30 1999-09-30 血小板由来増殖因子ｃ、それをコードするｄｎａ、及びその利用法

Country Status (5)

Country Link
EP (1) EP1123408A1 (fr)
JP (1) JP2002525086A (fr)
CN (1) CN1330664A (fr)
CA (1) CA2344561A1 (fr)
WO (1) WO2000018212A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531127A (ja) * 1998-12-07 2002-09-24 ザイモジェネティクス，インコーポレイティド 成長因子相同体ｚｖｅｇｆ３
JP2012504941A (ja) * 2008-10-09 2012-03-01 ファン、ラン 癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1064382T3 (da) 1998-03-17 2008-12-08 Genentech Inc Homologe polypeptider til VEGF og BMP1
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
WO2000059940A2 (fr) * 1999-04-06 2000-10-12 Eli Lilly And Company Gene et proteine lies au facteur de croissance d'origine plaquettaire
US6893637B1 (en) 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
CA2426384A1 (fr) * 2000-10-19 2003-04-17 Kyowa Hakko Kogyo Co., Ltd. Anticorps inhibant l'activite vplf
KR20080083072A (ko) * 2001-03-09 2008-09-12 얀센 파마슈티카 엔.브이. Ｖｅｇｆ-ｘ 또는 그의 길항제에 의한 평활근 세포 증식의 조절
EP1678197A4 (fr) * 2003-10-24 2008-05-07 Ludwig Inst Cancer Res Methodes et compositions d'activation et d'inhibition de pdgf-c
US20060024302A1 (en) 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
WO2005092921A2 (fr) * 2004-03-22 2005-10-06 Eli Lilly And Company Variants d'epissage du facteur de croissance placentaire, utilisations de ces derniers
WO2007022287A2 (fr) 2005-08-15 2007-02-22 Vegenics Limited Vegf-a modifié aux propriétés angiogéniques améliorées
ES2429225T3 (es) 2006-05-17 2013-11-13 The Ludwig Institute For Cancer Research Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico
KR20150005631A (ko) 2012-04-24 2015-01-14 쓰롬보제닉스 엔.브이. 항-pdgf-c 항체
CN104693286A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 关于血管内皮生长因子c拮抗多肽及其应用
CN104693285A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 血管内皮生长因子c拮抗多肽及其应用
CN104744565A (zh) * 2015-04-06 2015-07-01 苏州普罗达生物科技有限公司 一种血管内皮生长因子c拮抗多肽及其应用
CN105175546A (zh) * 2015-05-27 2015-12-23 连祺周 人血管内皮生长因子与表皮生长因子样结构域7的融合蛋白
AU2017290762A1 (en) * 2016-07-01 2019-01-31 Paracrine Therapeutics Ab Methods and compositions for PDGF-CC inhibition

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531127A (ja) * 1998-12-07 2002-09-24 ザイモジェネティクス，インコーポレイティド 成長因子相同体ｚｖｅｇｆ３
JP4739526B2 (ja) * 1998-12-07 2011-08-03 ザイモジェネティクス， インコーポレイテッド 成長因子相同体ｚｖｅｇｆ３
JP2012504941A (ja) * 2008-10-09 2012-03-01 ファン、ラン 癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用

Also Published As

Publication number Publication date
WO2000018212A9 (fr) 2000-09-08
EP1123408A1 (fr) 2001-08-16
CN1330664A (zh) 2002-01-09
CA2344561A1 (fr) 2000-04-06
WO2000018212A8 (fr) 2007-11-22
WO2000018212A2 (fr) 2000-04-06

Similar Documents

Publication Publication Date Title
US6706687B1 (en) Platelet-derived growth factor D
AU729880B2 (en) Recombinant vascular endothelial cell growth factor D (VEGF-D)
JP2002525086A (ja) 血小板由来増殖因子ｃ、それをコードするｄｎａ、及びその利用法
US7408040B2 (en) Antibodies to PDGF-D
JP2003517275A (ja) 哺乳動物ｖｅｇｆレセプター−２に結合し、これを活性化するオルフウイルスｎｚ２由来の血管内皮細胞増殖因子様タンパク質
US20070042413A1 (en) Platelet-derived growth factor D, DNA coding therefor, and uses thereof
US20020164687A1 (en) Platelet-derived growth factor C, DNA coding therefor, and uses thereof
US20070172423A1 (en) Composition and method for modulating vasculogenesis for angiogenesis
US20030211994A1 (en) Composition and method for modulating vasculogenesis or angiogenesis
JP2004504042A (ja) グリコシル化ｖｅｇｆ−ｂ及び可溶性ｖｅｇｆ−ｂの量を増加させるための方法
US20030082670A1 (en) Platelet-derived growth factor C, DNA coding therefor, and uses thereof
AU6502999A (en) Platelet-derived growth factor c, dna coding therefor, and uses thereof
JP2002535006A (ja) 血小板由来増殖因子／血管内皮増殖因子様増殖因子ｈとその利用法